Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Notebook: ‘No Urgent Need’ For Booster Vaccines, But EU & UK Advise Additional Doses In Immunocompromised

Executive Summary

ExeVir Bio has begun a Phase Ib study of its neutralizing antibody XVR011, NRx Pharmaceuticals has reported promising results with aviptadil in improving lung function, and Meletios Therapeutics has raised funds to further the development of an antiviral that acts on the SARS-CoV-2 virus and infected host cells.

You may also be interested in...



COVID-19: EU Assessing Booster Dose Of Pfizer/BioNTech’s Comirnaty

As the debate continues over whether booster vaccines will be required to sustain waning immune responses in the general population, the EU regulator says it should have the results of its assessment of an application for a booster dose of Cominarty in the next few weeks.

UK To Test Third Vaccine Dose In Immunocompromised People

Initial results of the OCTAVE DUO study are expected later this year and will feed into the UK’s deployment of COVID-19 vaccines in people with weakened immune systems.

Coronavirus Notebook: UK OKs Moderna Vaccine For Younger People, New Study Says Pfizer & AZ Vaccines Effective Against Delta Variant

Two antibody products, one from ExeVir Bio, the other from Tiziana Life Sciences, have shown efficacy against COVID-19 in clinical trials.

Topics

Related Companies

UsernamePublicRestriction

Register

PS144884

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel